ERNA ▼ -18.0% - Ernexa Therapeutics Inc. $ERNA - Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing Ernexa Therapeutics fell 18.0% today despite announcing positive preclinical data for its ERNA-201 candidate and progress toward first-in-human dosing of ERNA-101, suggesting investors may have been disappointed by the clinical stage of the data or concerns about the company's oncology pivot outweighed the positive developments. 15-SEP-2026 08:42 AM ET